Dr. Murray Orbuch, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 60
Licensed in California since 2020, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NY license 177500 · AZ license 41337 · CA license G169528 (first issued 2020; current) · FL license ME146278
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tucson Medical Center Tucson, AZ
Medical groups
- Tmc Medical Network (281 clinicians)
- Tmcone (96 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 60
- Services billed
- 156
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 42 | 29 |
| Established patient office or other outpatient visit, 30-39 minutes | 30 | 20 |
| Insertion of needle into vein for collection of blood sample | 25 | 23 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Famotidine Other prescribers in New York, NY | 35 |
| Pantoprazole Sodium Other prescribers in New York, NY | 28 |
| Levothyroxine Sodium Other prescribers in New York, NY | 18 |
| Amlodipine Besylate Other prescribers in New York, NY | 16 |
| Linzess (linaclotide) Other prescribers in New York, NY | 14 |
| Budesonide Dr (budesonide) Other prescribers in New York, NY | 12 |
| Celecoxib Other prescribers in New York, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 9 payments worth $5,673 in total to this clinician.
| Phathom Pharmaceuticals, Inc. | $3,706 |
|---|---|
| Histosonics, Inc. | $1,910 |
| Viiv Healthcare Company | $21.61 |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.93 |
| Pfizer Inc. | $16.51 |
| Compensation for services other than consulting (speaking, faculty) | $3,440 |
|---|---|
| Travel and Lodging | $1,962 |
| Food and Beverage | $272 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Histosonics, Inc. Jul 28, 2025 | Travel and Lodging travel to Plymouth, MN | $1,910 |
| Phathom Pharmaceuticals, Inc. Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Phathom Pharmaceuticals, Inc. Feb 26, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to NEW YORK, NY | $51.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $50,052 in research payments for these studies, mostly to the institutions running them.
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company · Active, not recruiting · NCT06598943 - UC P3: Double-Blind Treat Straight Through
Genentech, Inc. - Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
Genzyme Corporation · Active, not recruiting · NCT05588843
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.